Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.37 |
| ▸ | VHL | P40337 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10624291 | 0.85 | VHL (0.42) | F2VHLACEOPRD1 | |
| Rotigaptide SCHEMBL20547994 | 0.80 | VHL (0.49) | VHLOPRD1OPRM1 | |
| Rotigaptide SCHEMBL29359046 | 0.80 | VHL (0.49) | VHLOPRD1OPRM1 | |
| Rotigaptide SCHEMBL20547993 | 0.80 | VHL (0.49) | VHLOPRD1OPRM1 | |
| SCHEMBL16925996 | 0.80 | VHL (0.47) | VHLOPRD1OPRM1 | |
| SCHEMBL19381802 | 0.80 | VHL (0.47) | VHLOPRD1OPRM1 | |
| SCHEMBL10624289 | 0.79 | F2 (0.38) | F2ACEOPRD1OPRM1 | |
| SCHEMBL20626228 | 0.73 | VHL (0.52) | VHLOPRD1OPRM1 | |
| SCHEMBL20415545 | 0.71 | ACE (0.47) | F2DPP4ACEOPRD1OPRM1 | |
| SCHEMBL29795307 | 0.70 | VHL (0.40) | VHL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070168-A1 | GAP JUNCTION-ENHANCING AGENTS FOR TREATMENT OF NECROTIZING ENTEROCOLITIS AND INFLAMMATORY BOWEL DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070168-A1 | GAP JUNCTION-ENHANCING AGENTS FOR TREATMENT OF NECROTIZING ENTEROCOLITIS AND INFLAMMATORY BOWEL DISEASE | GJA1, VIP, GJB2 | F2 3644/4885VHL 3141/4885OXTR 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.